USE OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 7 AND TISSUE INHIBITOR OF METALLOPROTEINASE 2 IN THE MANAGEMENT OF RENAL REPLACEMENT THERAPY

The present invention provides methods and compositions for managing renal replacement therapy. A risk score, which is determined from a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and/or a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2),...

Full description

Saved in:
Bibliographic Details
Main Authors KAMPF, James, Patrick, MCPHERSON, Paul
Format Patent
LanguageEnglish
French
German
Published 06.01.2021
Subjects
CHEMISTRY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
TESTING
Online AccessGet full text

Cover

More Information
Summary:The present invention provides methods and compositions for managing renal replacement therapy. A risk score, which is determined from a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and/or a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.
Bibliography:Application Number: EP20180797960